{"entity":{"id":"tub-040","kind":"drug","name":"TUB-040","aka":[],"tldr":"TUB-040 is an experimental antibody-drug conjugate from Tubulis (Gilead), in phase 2 trials for platinum-resistant ovarian cancer, non-small cell lung cancer and endometrial cancer.","summary":"TUB-040 is an antibody-drug conjugate from Tubulis (Gilead), with Gilead Sciences as acquirer. An IgG1 antibody against NaPi2b joined to the topoisomerase I inhibitor exatecan through a cleavable linker made with Tubulis's P5 conjugation chemistry, with a drug-to-antibody ratio of 8. Its furthest stage is phase 2, for platinum-resistant ovarian cancer, non-small cell lung cancer (adenocarcinoma) and endometrial cancer. ClinicalTrials.gov registers it in 4 studies linked below. Tubulis pipeline page: Phase 1/2a (NAPISTAR 1-01, NCT06303505); Gilead acquisition release says Phase 1b/2. Highest registered stage is phase 2 (NCT07806773, phase 2a dose optimisation in NSCLC, not yet recruiting). FDA Fast Track for platinum-resistant ovarian cancer per Tubulis. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Tubulis (Gilead): tubulis.com","url":"https://tubulis.com/our-pipeline/"},{"label":"Tubulis (Gilead): tubulis.com","url":"https://tubulis.com/our-pipeline/"},{"label":"Tubulis (Gilead): tubulis.com","url":"https://tubulis.com/news/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline/"},{"label":"Tubulis (Gilead): clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07743541"},{"label":"ClinicalTrials.gov: trials of TUB-040","url":"https://clinicaltrials.gov/search?intr=TUB-040"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["platinum-resistant-ovarian-cancer","nsclc","endometrial"],"sections":[],"technologies":[],"targets":["slc34a2"],"drugs":[],"companies":["tubulis"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06303505","nct07736937","nct07743541","nct07806773"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"TUB-040","modality":"Antibody-drug conjugate","mechanism":"An IgG1 antibody against NaPi2b joined to the topoisomerase I inhibitor exatecan through a cleavable linker made with Tubulis's P5 conjugation chemistry, with a drug-to-antibody ratio of 8.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tub-040/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"target":[{"id":"slc34a2","kind":"target","name":"SLC34A2","route":"/targets/slc34a2/"}],"company":[{"id":"tubulis","kind":"company","name":"Tubulis (Gilead)","route":"/companies/tubulis/"}],"trial":[{"id":"nct06303505","kind":"trial","name":"FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC","route":"/trials/nct06303505/"},{"id":"nct07736937","kind":"trial","name":"Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer","route":"/trials/nct07736937/"},{"id":"nct07806773","kind":"trial","name":"Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer","route":"/trials/nct07806773/"},{"id":"nct07743541","kind":"trial","name":"Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy","route":"/trials/nct07743541/"}]}}